Business
Artisan Therapeutics and Tulex Pharmaceuticals Announce Positive Phase 2a Results for ART-501, a Novel Oral Liquid Extended-Release Formulation for Autism Spectrum Disorder
Artisan and Tulex Report Positive Phase 2a Results for Autism Drug ART-501SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Artisan Therapeutics, Inc. (“Artisan”) and Tulex Pharmaceuticals (“Tulex”) today announced encouraging Phase 2a clinical results highlighting the potential of ART-501 for the treatment of autism spectrum disorder (“ASD”)-related conditions. In this pilot, proof-of-concept study, four out of six participants demonstrated meaningful signs of clinical benefit. ART-501 was generally
About this update from Easywell Biomedicals, Inc.
[{"type":"image","alt":"Artisan Therapeutics","displaySize":"","headline":null,"caption":"Artisan Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/845acb7dcb95e13439aebde97fe577a1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dWPLfLrbUdUZNmqgF2gsTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/845acb7dcb95e13439aebde97fe577a1","width":300,"height":300}},"lazy":false},{"type":"text","content":"Artisan and Tulex Report Positive Phase 2a Results for Autism Drug ART-501","length":74,"tagName":"p"},{"type":"text","content":"SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Artisan Therapeutics, Inc. (“Artisan”) and Tulex Pharmaceuticals (“Tulex”) today announced encouraging Phase 2a clinical results highlighting the potential of ART-501 for the treatment of autism spectrum disorder (“ASD”)-related conditions. In this pilot, proof-of-concept study, four out of six participants demonstrated meaningful signs of clinical benefit. ART-501 was generally well-tolerated, with adverse events reported as mostly mild and transient, and with no serious adverse events observed.","length":546,"tagName":"p"},{"type":"text","content":"Behavioral improvements, as measured by the Aberrant Behavior Checklist – Second Edition (ABC-2), were observed in the majority of participants, with notable reductions seen in the ABC-2 subscales for irritability, lethargy/social withdrawal, stereotypic behaviors, and hyperactivity/non-compliance during low-dose ART-501 dosing compared to baseline. The ABC-2 irritability subscale is an established clinical measure that has served as a primary endpoint in FDA-approved therapies for irritability associated with ASD.","length":520,"tagName":"p"},{"type":"text","content":"The pilot Phase 2a study was a multicenter trial conducted at two U.S. clinical sites that enrolled six adult participants with diagnostically confirmed ASD, five of whom completed treatment. The trial consisted of baseline assessments followed by an open-label period involving low-dose ART-501, then by a blinded, placebo-controlled, crossover period involving higher-dose ART-501.","length":383,"tagName":"p"},{"type":"text","content":"Dr. Ann Childress, M.D., who was an investigator in the trial, stated, “Autism presents sign...